Stock HAVN HAVN LIFE SCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company HAVN Life Sciences Inc.

Equities

HAVN

CA4196213058

Biotechnology & Medical Research

Delayed Canadian Securities Exchange
Other stock markets
 19:12:37 09/11/2023 GMT 		5-day change 1st Jan Change
0.03 CAD -.--% Intraday chart for HAVN Life Sciences Inc. +20.00% -.--%
2023 HAVN Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023 CI
2023 HAVN Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022 CI

Business Summary

HAVN Life Sciences Inc. is a Canada-based biotechnology company. The Company is engaged in the scientific research and development of psychopharmacological and natural health care products. It is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing mental health treatments to support brain health and enhance the capabilities of the mind. The Company has two business divisions: HAVN Labs and HAVN Retail. The HAVN Labs division is engaged in the development of research protocols to cover the production of Psilocybe spp. Through its research division, HAVN Labs, it has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research. The HAVN Retail division formulates and sells natural health products (NHPs) using compounds. It offers a full range of mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Sales per Business

CAD in Million2021Weight2022Weight Delta
Psychoactive Compounds, Development of Natural Health Care Products, and Mental Health Treatments
100.0 %
0 nan % 0 100.0 % -

Sales per region

CAD in Million2021Weight2022Weight Delta
Canada
100.0 %
0 nan % 0 100.0 % -

Managers

Managers TitleAgeSince
Tim Moore CEO
 Chief Executive Officer 66 05/05/20
Jenna Pozar COO
 Chief Operating Officer - 28/02/21
Alexzander Samuelsson BRD
 Director/Board Member - 03/09/20
Ivan Casselman BRD
 Director/Board Member - -

Members of the board

Members of the board TitleAgeSince
Tim Moore CEO
 Chief Executive Officer 66 05/05/20
Ivan Casselman BRD
 Director/Board Member - -
Alexzander Samuelsson BRD
 Director/Board Member - 03/09/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 28,646,020 27,642,020 ( 96.50 %) 0 96.50 %

Shareholders

NameEquities%Valuation
ABO Infinium Americas OpCo Ltd.
0.000000 %
0 0.000000 % - $

Company contact information

HAVN Life Sciences, Inc.

130 Brew Street Suite 605

V3H 0E3, Port Moody

+604 370 9520

http://www.havnlife.com
address HAVN Life Sciences Inc.(HAVN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
HAVN LIFE SCIENCES INC. Stock HAVN Life Sciences Inc.
-.--% 625K
MODERNA, INC. Stock Moderna, Inc.
+18.17% 42.68B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.76% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+45.15% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.12% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.62% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.44% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.52% 11.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.81% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. HAVN Stock
  4. Company HAVN Life Sciences Inc.